+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Blood Cancer Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Blood Cancer Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Blood Cancer Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6010967
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Blood Cancer Drugs Market grew from USD 45.98 billion in 2024 to USD 50.96 billion in 2025. It is expected to continue growing at a CAGR of 10.33%, reaching USD 82.96 billion by 2030.

Blood cancers, encompassing leukemia, lymphoma, and myeloma, represent a complex and evolving therapeutic frontier. The convergence of scientific breakthroughs-ranging from targeted therapies and immuno-oncology advances to precision diagnostics-has transformed the clinical landscape, challenging stakeholders to navigate a rapidly shifting environment. This executive summary distills prevailing trends, policy implications, and market segmentation insights to inform strategic decisions and optimize patient outcomes. By synthesizing the latest innovations, regulatory developments, and competitive dynamics, this overview equips industry leaders with a cohesive understanding of current drivers and future opportunities within the blood cancer therapeutics arena.

Transformative Shifts Redefining Blood Cancer Treatment Dynamics

Over the past five years, paradigm shifts have redefined the blood cancer treatment ecosystem. First, the maturation of immunotherapy has elevated checkpoint inhibitors and cancer vaccines to frontline consideration, complementing advances in cytokine-based approaches. Concurrently, the surge in chimeric antigen receptor T-cell therapy has validated cell-based modalities, prompting investment in scalable manufacturing and enhanced safety profiles. Moreover, the proliferation of targeted agents-especially tyrosine kinase inhibitors, proteasome inhibitors, and cyclin-dependent kinase inhibitors-has enabled personalized intervention tailored to molecular disease subtypes.

At the same time, digital health integration-from remote patient monitoring to AI-driven diagnostic algorithms-has accelerated clinical trial enrollment and real‐world evidence generation. Regulatory bodies have responded with adaptive pathways and accelerated review designations, facilitating faster patient access while balancing safety considerations. Finally, an increased emphasis on health economics and value-based contracting is reshaping pricing models and stakeholder engagement. Together, these transformative forces underscore a dynamic landscape in which agility, collaboration, and innovation are paramount.

Assessing the Cumulative Impact of United States Tariffs in 2025

With the implementation of new tariff schedules in 2025, import duties on active pharmaceutical ingredients and finished formulations have risen notably, influencing cost structures across the supply chain. Domestic producers face incentives to localize manufacturing to mitigate duty burdens, whereas international suppliers are reevaluating sourcing strategies to preserve margins. These higher input costs are likely to cascade into pricing negotiations, placing pressure on reimbursement frameworks and potentially impacting patient access if payers adopt stricter formulary controls.

Moreover, tariff-driven volatility has heightened the importance of strategic inventory management and multilayered supplier networks to prevent supply interruptions. In parallel, government stakeholders are engaging in bilateral talks to harmonize trade policies and explore tariff exemptions for critical oncology therapies. Consequently, industry participants must balance short-term mitigation tactics, such as forward contracting and tariff engineering, with long-term structural shifts toward regional manufacturing hubs and integrated supply ecosystems.

In-Depth Segmentation Insights Driving Market Complexity

Analysis across drug types reveals that targeted therapy continues to outpace traditional chemotherapy drug segments, driven by robust uptake of monoclonal antibodies and tyrosine kinase inhibitors, while next-generation proteasome inhibitors maintain momentum through niche positioning in multiple myeloma. Immunotherapy drugs, including checkpoint inhibitors and cancer vaccines, are rapidly carving out share, supported by cytokine adjuncts that enhance treatment efficacy. Despite this, bone marrow and stem cell transplantation sustain a critical role in curative paradigms, particularly when integrated with consolidation and maintenance therapeutic approaches.

When dissecting disease categories, acute lymphoblastic leukemia and acute myeloid leukemia exhibit heightened trial activity in induction and consolidation therapy pipelines, whereas chronic lymphocytic leukemia and chronic myeloid leukemia show a shift toward oral maintenance regimens. In the lymphoma domain, both Hodgkin and non-Hodgkin subtypes benefit from combination strategies that align monoclonal antibodies with traditional cytotoxic backbones. Meanwhile, multiple myeloma treatments increasingly emphasize long-term management via chronic maintenance protocols.

Within the mode of administration dimension, oral therapies are gaining share over intravenous and subcutaneous delivery, reflecting patient preference for outpatient regimens and reduced hospital burden. Hospitals remain the primary end-user channel, though specialty clinics and retail pharmacies are emerging as key access points for subcutaneous and self-administered formulations. Pharmaceutical companies continue to invest in patient support programs to drive adherence across adults, children, and geriatric cohorts, recognizing that demographic variation influences tolerance and dosing schedules.

Treatment duration stratification reveals that chronic maintenance accounts for a growing proportion of therapy days compared to short-term induction cycles, underscoring the shift toward sustained disease control. Development stage analysis highlights that the approved segment dominates current revenues, but a robust clinical trial pipeline suggests significant future value locked in pre-clinical and early-phase programs. Finally, across lines of therapy, first-line agents lead adoption curves, yet second- and third-line options are critical for refractory or relapsed populations, driving diversified portfolio strategies.

Regional Outlook: Growth Drivers and Market Penetration across Territories

The Americas continue to lead in innovation uptake and clinical trial activity, underpinned by well-established reimbursement pathways and substantial R&D investment. Within the United States, premium pricing mechanisms support novel immunotherapies and cell therapies, though payer scrutiny is intensifying around cost-effectiveness. In contrast, Latin American markets exhibit uneven access, prompting manufacturers to collaborate with local health ministries to expand treatment availability through tiered pricing models.

Europe, the Middle East & Africa present a heterogeneous landscape: Western Europe’s centralized procurement systems facilitate rapid inclusion of breakthrough therapies, while Central and Eastern European nations vary in reimbursement capacity, influencing launch sequences. Middle Eastern countries are investing in healthcare infrastructure and forging partnerships to accelerate adoption, whereas African markets face supply chain and infrastructure challenges that require capacity-building initiatives.

Asia-Pacific is characterized by divergent regulatory frameworks and growing domestic manufacturing capabilities. Japan and South Korea demonstrate early adoption of targeted and immuno-oncology agents, supported by favorable reimbursement decisions. China’s market, buoyed by recent reforms to promote local innovation, is rapidly expanding its clinical trial footprint, while Southeast Asian nations are focusing on public-private partnerships to enhance treatment penetration.

Competitive Landscape and Key Player Strategies Shaping the Future

The competitive landscape is led by large multinational pharmaceutical firms with extensive oncology portfolios, complemented by emerging biotech companies pushing novel mechanisms of action. AbbVie’s strategic acquisitions have broadened its hematology pipeline, while Amgen’s investments in biomanufacturing capacity underscore its commitment to cell-based therapy scalability. AstraZeneca and Bristol-Myers Squibb are leveraging checkpoint inhibitor combinations, and Celgene’s integration into a larger oncology network has accelerated development timelines.

Daiichi Sankyo and Eisai are focusing on antibody-drug conjugates, exploring synergistic potential with existing backbone regimens. Roche and Gilead maintain strong positions in targeted therapy, with Roche’s proteasome inhibitors and Gilead’s kinase inhibitors driving robust sales. Meanwhile, GlaxoSmithKline and Johnson & Johnson are diversifying into immunotherapeutic vaccines and cytokine approaches. Incyte and Karyopharm Therapeutics are carving niche positions in small-molecule inhibitors, with Merck & Co. and Novartis further bolstering their immuno-oncology pipelines through strategic alliances.

Pfizer and Sanofi are pursuing global expansion of their hematology franchises, whereas Seattle Genetics and Takeda are co-developing antibody conjugates tailored to specific hematologic indications. Across the board, companies are prioritizing real-world evidence generation and value-based contracting to address payer demands and reinforce product differentiation.

Actionable Recommendations for Industry Leaders to Accelerate Success

First, industry leaders should accelerate investment in localized manufacturing and supply chain diversification to mitigate tariff exposure and ensure uninterrupted access. Second, aligning development pipelines with precision medicine initiatives-such as companion diagnostics and biomarker-driven trials-will enhance clinical differentiation and payer receptivity. Third, integrating digital solutions for patient monitoring and adherence can reduce therapeutic attrition and strengthen value propositions during reimbursement negotiations.

Furthermore, forging cross-sector partnerships between biotech innovators and large pharmaceutical companies can expedite commercialization timelines while sharing risk. Leaders should also prioritize engagement with regulatory authorities to shape adaptive approval paradigms and secure accelerated pathways. Finally, adopting flexible pricing models-encompassing outcome-based agreements and tiered access arrangements-will be crucial to balancing innovation incentives with broader affordability imperatives.

Conclusion: Strategic Imperatives for Sustained Innovation

The current blood cancer therapeutics environment presents both complex challenges and unprecedented opportunities. By embracing targeted innovation, agile supply chain strategies, and value-based engagement with payers, stakeholders can navigate tariff pressures and regional disparities while advancing patient-centric outcomes. Continued collaboration across industry, regulators, and healthcare providers will be essential to unlock the full potential of emerging modalities, from cell and gene therapies to precision-driven treatment algorithms.

Market Segmentation & Coverage

This research report categorizes the Blood Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Bone Marrow Transplantation
  • Chemotherapy Drugs
    • Alkylating Agents
    • Anthracyclines
    • Antimetabolites
    • Plant Alkaloids
  • Immunotherapy Drugs
    • Cancer Vaccines
    • Checkpoint Inhibitors
    • Cytokines
  • Stem Cell Transplantation
  • Targeted Therapy Drugs
    • Cyclin-Dependent Kinase Inhibitors
    • Monoclonal Antibodies
    • Proteasome Inhibitors
      • Bortezomib
      • Carfilzomib
    • Tyrosine Kinase Inhibitors
  • Leukemia
    • Acute Lymphoblastic Leukemia
    • Acute Myeloid Leukemia
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
  • Lymphoma
    • Hodgkin Lymphoma
    • Non-Hodgkin Lymphoma
  • Myeloma
  • Consolidation Therapy
  • Induction Therapy
  • Maintenance Therapy
  • Intravenous
  • Oral
  • Subcutaneous
  • Hospitals
  • Pharmaceutical Companies
  • Retail Pharmacies
  • Specialty Clinics
  • Adults
  • Children
  • Geriatric
  • Long-Term
    • Chronic Maintenance
  • Short-Term
  • Approved
  • Clinical Trials
  • Pre-Clinical
  • First-Line Therapy
  • Second-Line Therapy
  • Third-Line Therapy

This research report categorizes the Blood Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Blood Cancer Drugs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Blood Cancer Drugs Market, by Drug Type
8.1. Introduction
8.2. Bone Marrow Transplantation
8.3. Chemotherapy Drugs
8.3.1. Alkylating Agents
8.3.2. Anthracyclines
8.3.3. Antimetabolites
8.3.4. Plant Alkaloids
8.4. Immunotherapy Drugs
8.4.1. Cancer Vaccines
8.4.2. Checkpoint Inhibitors
8.4.3. Cytokines
8.5. Stem Cell Transplantation
8.6. Targeted Therapy Drugs
8.6.1. Cyclin-Dependent Kinase Inhibitors
8.6.2. Monoclonal Antibodies
8.6.3. Proteasome Inhibitors
8.6.3.1. Bortezomib
8.6.3.2. Carfilzomib
8.6.4. Tyrosine Kinase Inhibitors
9. Blood Cancer Drugs Market, by Disease Type
9.1. Introduction
9.2. Leukemia
9.2.1. Acute Lymphoblastic Leukemia
9.2.2. Acute Myeloid Leukemia
9.2.3. Chronic Lymphocytic Leukemia
9.2.4. Chronic Myeloid Leukemia
9.3. Lymphoma
9.3.1. Hodgkin Lymphoma
9.3.2. Non-Hodgkin Lymphoma
9.4. Myeloma
10. Blood Cancer Drugs Market, by Therapeutic Approach
10.1. Introduction
10.2. Consolidation Therapy
10.3. Induction Therapy
10.4. Maintenance Therapy
11. Blood Cancer Drugs Market, by Mode of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Blood Cancer Drugs Market, by End-User
12.1. Introduction
12.2. Hospitals
12.3. Pharmaceutical Companies
12.4. Retail Pharmacies
12.5. Specialty Clinics
13. Blood Cancer Drugs Market, by Age Group
13.1. Introduction
13.2. Adults
13.3. Children
13.4. Geriatric
14. Blood Cancer Drugs Market, by Duration of Treatment
14.1. Introduction
14.2. Long-Term
14.2.1. Chronic Maintenance
14.3. Short-Term
15. Blood Cancer Drugs Market, by Development Stage
15.1. Introduction
15.2. Approved
15.3. Clinical Trials
15.4. Pre-Clinical
16. Blood Cancer Drugs Market, by Line of Therapy
16.1. Introduction
16.2. First-Line Therapy
16.3. Second-Line Therapy
16.4. Third-Line Therapy
17. Americas Blood Cancer Drugs Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Blood Cancer Drugs Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Blood Cancer Drugs Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. AbbVie Inc.
20.3.2. Amgen Inc.
20.3.3. AstraZeneca PLC
20.3.4. bluebird bio, Inc.
20.3.5. Bristol-Myers Squibb Company
20.3.6. Celgene Corporation
20.3.7. Daiichi Sankyo Company, Limited
20.3.8. Eisai Co., Ltd.
20.3.9. F. Hoffmann-La Roche Ltd
20.3.10. Gilead Sciences, Inc.
20.3.11. GlaxoSmithKline plc
20.3.12. Incyte Corporation
20.3.13. Johnson & Johnson
20.3.14. Karyopharm Therapeutics Inc.
20.3.15. Merck & Co., Inc.
20.3.16. Novartis International AG
20.3.17. Pfizer Inc.
20.3.18. Sanofi S.A.
20.3.19. Seattle Genetics, Inc.
20.3.20. Takeda Pharmaceutical Company Limited
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. BLOOD CANCER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. BLOOD CANCER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. BLOOD CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 24. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. BLOOD CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. BLOOD CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLOOD CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY BONE MARROW TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CONSOLIDATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 120. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 122. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 123. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 124. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 126. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 127. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 128. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 129. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 133. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 134. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 135. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 142. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 148. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 202. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 203. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 204. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 205. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 206. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 207. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 208. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 209. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 210. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 211. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 214. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 215. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 216. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 217. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 218. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 219. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 220. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 221. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 222. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 224. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 225. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 226. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 227. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 230. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 231. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 232. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 233. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 250. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 251. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 252. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 253. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 254. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 255. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 256. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 257. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 258. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 259. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 261. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 262. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 263. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 264. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 265. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 269. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 270. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 272. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 273. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 274. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 275. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 278. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 279. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 280. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 281. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 282. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 283. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 284. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 285. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 286. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 298. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 299. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 300. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 301. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 302. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 303. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 312. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 313. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 316. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 317. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 318. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 319. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 320. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 321. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 322. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 323. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 325. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 326. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 327. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 328. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 329. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 330. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 331. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 332. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 333. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 334. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 335. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 336. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 337. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 338. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 339. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY MODE OF ADMINIS

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Blood Cancer Drugs Market Report 2025 - Product Image

Blood Cancer Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 80 Pages
  • Global
From
Doxorubicin Market by Drug Formulation, Distribution Channel, Application - Global Forecast 2025-2030 - Product Image

Doxorubicin Market by Drug Formulation, Distribution Channel, Application - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Capecitabine Market by Drug Formulation, Distribution Channel, End Users, Drug Type - Global Forecast 2025-2030 - Product Image

Capecitabine Market by Drug Formulation, Distribution Channel, End Users, Drug Type - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Bruton's Tyrosine Kinase Hematological Cancer - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Bruton's Tyrosine Kinase Hematological Cancer - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Blood Cancer Drug Market

The Blood Cancer Drug market is a subset of the Oncology Drugs market, which focuses on the treatment of cancer. Blood cancer drugs are used to treat a variety of blood cancers, including leukemia, lymphoma, and myeloma. These drugs are typically administered intravenously or orally, and may include chemotherapy, targeted therapy, and immunotherapy. Blood cancer drugs are designed to target cancer cells while minimizing damage to healthy cells, and may be used in combination with other treatments. The Blood Cancer Drug market is highly competitive, with a number of large pharmaceutical companies offering a range of treatments. Companies in the market include Novartis, Pfizer, Bristol-Myers Squibb, Celgene, and Merck. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.